Menu
Recruiting NCT04760574

Association Between Human Immunodeficiency Virus (HIV) Infection and Male Hypogonadism

— Observational Hypogonadism; Ovarian

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: Testosterone.
Who it may be relevant to
Registry conditions: Hypogonadism; Ovarian. Basic parameters: from 20 years · Male.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
Taiwan
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →

Unsure about the terms? Read our patient guide →

Overview

Cross-sectional study investigating the prevalence of hypogonadism in HIV-infected MSM population

Detailed description

In this study, we conduct a cross-sectional study investigating the prevalence of hypogonadism in HIV-infected MSM population. Age-matched non-HIV infected MSM group will be used as comparison group. We will also determine the risk factors associated with male hypogonadism (age, duration of HIV infection, comorbidities, BMI, ART use). Correlation will be made between serum testosterone levels and sexual function, vitality, exercise capacity, mood, and bone mineral density.

Interventions

  • Diagnostic test Testosterone
    Serum total testosterone and free testosterone level

Primary outcome measures

  • Symptoms of androgen deficiency [Time frame: 2021-2030]
  • Serum free testosterone [Time frame: 2021-2030]

Eligibility criteria

Inclusion criteria

  • HIV-infected men who have sex with men
  • HIV non-infected men

Exclusion criteria

  • Use of testosterone supplement, anabolic steroid in the past one year.
  • History of pituitary , adrenal or gonad diseases
  • History of pituitary surgery or radiation therapy
  • History of systemic chemotherapy
  • Active opportunistic infection under treatment
  • Cancer
  • Severe hepatic, renal or cardiac impairment

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: Yes

Study design

Observational model
Cohort

Study locations

Taiwan · 1 center
  • National Taiwan University Hospital — Taipei

Identifiers

NCT: NCT04760574 · 202010105RIND

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗